| Datum | Källa | Rubrik | Typ | Alternativ |
|---|---|---|---|---|
| 2024-06-13 | Enzymatica | Enzymatica AB: Interim results from independent clinical study of ColdZyme® show duration of illness lowered by approximately 5 days | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-06-13 | Enzymatica | Enzymatica AB: Interimsresultat från oberoende klinisk studie av ColdZyme® visar att sjukdomstiden minskar med cirka 5 dagar | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-05-07 | Enzymatica | Bulletin from annual general meeting of Enzymatica AB (publ) on May 7, 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-05-07 | Enzymatica | Kommuniké från årsstämma i Enzymatica AB (publ) den 7 maj 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-04-29 | Enzymatica | Enzymatica AB: BioStock: MDR certification was Enzymatica's highlight in Q1 | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-04-29 | Enzymatica | Enzymatica AB: BioStock: MDR-certifieringen var Enzymaticas höjdpunkt under Q1 | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-04-29 | Penser Access by Carnegie | Penser Access by Carnegie: Enzymatica - Behöver se en vändning | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-04-26 | Redeye | Redeye: Enzymatica Q1 - Continued growth in own markets, but a lack of partner orders | Pressreleaser | Ladda ner | Visa Stäng |
|
Pressreleaser |
Redeye: Enzymatica Q1 – Continued growth in own markets, but a lack of partner ordersRedeye provides an update following Enzymatica’s Q1 report. The quarter’s sales did not meet our expectations, which resulted from low partner orders. We argue the company has an important time ahead and view a rise in partner sales as a trigger for the share. Moreover, we make changes to our sales estimates, rendering an updated fair value range. Read more and download the Research Update. |
||||
| 2024-04-25 | Enzymatica | Enzymatica AB: Interim report Q1/2024: MDR certification opens up great commercial opportunities | Rapporter | Ladda ner | Visa Stäng |
|
|
||||
| 2024-04-25 | Enzymatica | Enzymatica AB: Delårsrapport Q1/2024: MDR-certifieringen öppnar stora kommersiella möjligheter | Rapporter | Ladda ner | Visa Stäng |
|
|
||||
| 2024-04-09 | Enzymatica | Enzymatica AB: Enzymatica publishes annual report for 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-04-09 | Enzymatica | Enzymatica AB: Enzymatica publicerar årsredovisning för 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-03-27 | Enzymatica | Kallelse till årsstämma 2024 i Enzymatica AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-03-27 | Enzymatica | Notice of Annual General Meeting 2024 in Enzymatica AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-03-20 | Enzymatica | Enzymatica AB: BioStock: Enzymatica kommenterar MDR-certifieringen för ColdZyme | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-03-20 | Enzymatica | Enzymatica AB: BioStock: Enzymatica comments on MDR certification for ColdZyme | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-03-14 | Enzymatica | Enzymatica AB: Enzymatica offentliggör utfall i företrädesemissionen | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-03-14 | Enzymatica | Enzymatica AB: Enzymatica announces outcome of new rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-03-11 | Enzymatica | Enzymatica AB: ColdZyme® certified under the new EU medical device regulation (MDR) | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-03-11 | Enzymatica | Enzymatica AB: Enzymaticas munspray ColdZyme® erhåller CE-certifiering enligt nya EU-förordningen MDR | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-03-04 | Enzymatica | Enzymatica AB: BioStock: Enzymatica förbereder för expansion genom emission | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-02-26 | Enzymatica | Enzymatica AB: BioStock: Enzymatica's partners await MDR certification and study results | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-02-26 | Enzymatica | Enzymatica AB: BioStock: Enzymaticas partners inväntar MDR-certifiering och studieresultat | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-02-20 | Penser Access by Carnegie | Penser Access by Carnegie: Enzymatica - Lägger ännu ett tufft år bakom sig | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-02-19 | Enzymatica | Enzymatica AB: Enzymatica publishes information memorandum about rights issue of shares | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-02-19 | Enzymatica | Enzymatica AB: Enzymatica offentliggör informationsmemorandum med anledning av företrädesemission av aktier | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-02-19 | Redeye | Redeye: Enzymatica Q4 - Important year ahead and an expected rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-02-16 | Enzymatica | Enzymatica AB: Enzymatica's rights issue is secured to 100 percent | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-02-16 | Enzymatica | Enzymatica AB: Enzymaticas nyemission är säkerställd till 100 procent | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-02-16 | Enzymatica | Enzymatica AB: Year-end report 2023: Scientific and regulatory progress generating international interest | Rapporter | Ladda ner | Visa Stäng |
|
|
||||
| 2024-02-16 | Enzymatica | Enzymatica AB: Bokslutskommuniké 2023: Vetenskapliga och regulatoriska framsteg skapar internationellt intresse | Rapporter | Ladda ner | Visa Stäng |
|
|
||||
| 2024-02-16 | Enzymatica | Enzymatica AB: Styrelsen i Enzymatica beslutar om nyemission om 27,4 MSEK | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-02-16 | Enzymatica | Enzymatica AB: Enzymatica's Board of Directors decides on a new rights issue of SEK 27.4 million | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-12-21 | Enzymatica | Enzymatica AB: Enzymatica's Chairman to BioStock: "Our new research data makes 2024 an exciting year" | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-12-21 | Enzymatica | Enzymatica AB: Enzymaticas ordförande till BioStock: "Våra nya forskningsdata gör 2024 till ett spännande år" | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-11-30 | Enzymatica | Enzymatica AB: Enzymatica changes Certified Adviser to Carnegie Investment Bank AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-11-30 | Enzymatica | Enzymatica AB: Enzymatica byter Certified Adviser till Carnegie Investment Bank AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-11-08 | Penser Access | Penser Access: Fortsatt svaga försäljningssiffror - Enzymatica | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-11-08 | Enzymatica | Enzymatica AB: BioStock: Enzymatica focuses on strengthening the distributor level | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-11-08 | Enzymatica | Enzymatica AB: BioStock: Enzymatica arbetar för att stärka distributörsledet | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-11-08 | Redeye | Redeye: Enzymatica Q3 - The STADA partnership creating concerns about the future | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-11-07 | Enzymatica | Enzymatica AB: Kvartalsrapport Q3/2023: Forskningsresultat som förändrar spelplanen | Rapporter | Ladda ner | Visa Stäng |
|
|
||||
| 2023-11-07 | Enzymatica | Enzymatica AB: Interim report Q3/2023: Research results that reshape the competitive landscape | Rapporter | Ladda ner | Visa Stäng |
|
|
||||
| 2023-09-22 | Enzymatica | Enzymatica AB: BioStock: Enzymaticas ColdZyme minskar mängden rhinovirus och halsont | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-09-21 | Enzymatica | Enzymatica AB: Delrapport från klinisk studie: ColdZyme minskar signifikant mängden rhinovirus samt symptom på halsont | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-09-21 | Enzymatica | Enzymatica AB: Interim report from clinical study: ColdZyme significantly reduces rhinovirus viral load and symptoms of sore throat | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-08-24 | Enzymatica | Enzymatica AB: BioStock: Enzymaticas vd kommenterar lovande in-vitro data för ColdZyme | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-08-24 | Enzymatica | Enzymatica AB: BioStock: Enzymatica's CEO comments on promising in-vitro data for ColdZyme | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-08-22 | Enzymatica | Enzymatica AB: New study: ColdZyme breaks viral infection cycle - significantly reducing influenza viral load | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-08-22 | Enzymatica | Enzymatica AB: Ny studie: ColdZyme bryter infektionscykeln och minskar mängden influensavirus signifikant | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-07-19 | Redeye | Redeye: Enzymatica Q2 2023 - Waiting for the cold season | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-07-18 | Penser Access | Penser Access: Kommande studieresultat i fokus - Enzymatica | Pressreleaser | Visa Stäng |
|
|
||||
| 2023-07-18 | Enzymatica | Enzymatica AB: Kvartalsrapport Q2/2023: En spännande och viktig tid framöver | Rapporter | Ladda ner | Visa Stäng |
|
|
||||
| 2023-07-18 | Enzymatica | Enzymatica AB: Interim report Q2/2023: An exciting and important time ahead | Rapporter | Ladda ner | Visa Stäng |
|
|
||||
Kommande händelser